
USA Today via Reuters
Atlanta Braves players, from left, outfielders Jurickson Profar, and infielders Ozzie Albie and Orlando Arcia, arrive for a spring training workout Thursday, Feb. 27th at CoolToday Park in North Port. | Mike Lang / Sarasota Herald-Tribune / USA TODAY NETWORK via Imagn Images

USA Today via Reuters
Atlanta Braves players, from left, outfielders Jurickson Profar, and infielders Ozzie Albie and Orlando Arcia, arrive for a spring training workout Thursday, Feb. 27th at CoolToday Park in North Port. | Mike Lang / Sarasota Herald-Tribune / USA TODAY NETWORK via Imagn Images
MLB teams need to take a stronger initiative to prevent doping cases. Some players appear to be ignoring the consequences of getting caught, as seen with Atlanta Braves outfielder Jurickson Profar, who has reportedly tested positive again.
ESPN insider Jeff Passan reported, “Jurickson Profar facing 162-game suspension after testing positive for a performance-enhancing drug for the second time.”
Watch What’s Trending Now!
According to him, Profar now faces a 162-game suspension after failing another PED test. If the suspension is upheld, he will forfeit his $15 million salary and become ineligible for the postseason under MLB’s drug policy.
This would mark the sixth full-season PED suspension since MLB strengthened penalties for repeat offenders in 2014. For Atlanta, it could mean losing a projected designated hitter before lineup plans are finalized heading into the 2026 season. Fans hoping for stability now face another unexpected absence tied to league discipline rather than injury.
The situation carries added weight because Profar already served an 80-game suspension that began on March 31, 2025. That penalty followed a positive test for hCG, a hormone linked to testosterone production under MLB rules. The suspension made him ineligible for the 2025 postseason and removed him from half of the regular-season schedule.
Atlanta struggled during that period, scoring only seven runs in an opening series sweep. Losing a middle-of-the-order bat during that stretch forced the team into constant lineup adjustments while injuries were already testing the roster’s depth.
When the Braves signed Jurickson Profar to a three-year, $42 million contract, expectations rose across the clubhouse and the fan base. The deal followed a strong season that convinced Atlanta he could provide stability in the everyday lineup.
Passan: Jurickson Profar facing 162-game suspension after testing positive for a performance-enhancing drug for the second time.
— Underdog MLB (@UnderdogMLB) March 3, 2026
The team had projected him to bat near Ronald Acuña Jr., likely filling the designated hitter role. Instead, missing games across consecutive seasons means he will lose at least half of the contract’s scheduled appearances.
This latest suspension leaves Atlanta adjusting once again, despite adding Mike Yastrzemski earlier to strengthen its outfield depth. With neither Profar nor Marcell Ozuna firmly projected in the lineup, the Braves must redistribute plate appearances before the season begins.
His absence places greater offensive responsibility on Matt Olson, Austin Riley, and Ozzie Albies. The situation is further complicated by pitching concerns, as Spencer Schwellenbach and Hurston Waldrep have already landed on the injured list with elbow issues.
Under MLB policy, this suspension represents Profar’s second violation and carries consequences beyond a single season. League rules impose an 80-game suspension for a first offense, 162 games for a second offense, and a lifetime ban after a third violation.
The Braves previously expressed disappointment when Profar’s first suspension occurred in 2025. At the time, manager Brian Snitker said he respected the league’s decision and supported its enforcement. The organization is expected to take a similar stance if the current suspension is upheld.
Although Profar is expected to appeal the ruling, many fans believe that being caught again undermines the apology he issued after the first incident.
History also shows how serious repeat violations can become. Players such as J.C. Mejía never returned to affiliated baseball after receiving similar penalties in September 2023. That reality now hangs over the situation, reminding observers how narrow the path forward has become. For Jurickson Profar, avoiding another violation is no longer just about redemption but about continuing his major league career.
With Profar, who can the Atlanta Braves replace him with?
Jurickson Profar may have derailed his own 2026 season, but the Atlanta Braves cannot afford the same setback. Alex Anthopoulos now faces one of the toughest offseasons of his tenure after Profar’s suspension. Losing a projected cleanup hitter leaves a major gap in the lineup. With limited elite free agents available, Anthopoulos’ next move could define Atlanta’s credibility heading into the season.
One name generating trade buzz is Georgia native Byron Buxton. In 2025, he hit 35 home runs and stole 24 bases in 126 games while posting an .878 OPS. His combination of power and speed makes him one of the most dynamic hitters available.
Atlanta could offer top prospects such as 20-year-old right-hander Didier Fuentes and 17-year-old outfielder Diego Tornes in a potential deal. Both rank among the Braves’ most promising young talents and could interest Minnesota.
The Twins may be open to discussions after finishing 70-92 in 2025, which has fueled speculation about a rebuild. Their offense struggled last year, and Buxton could bring back multiple high-impact prospects. However, his no-trade clause adds another layer of complexity.
If a major trade does not materialize, Atlanta may have to explore weaker alternatives. Free agents like Tommy Pham or Max Kepler are available, but neither replaces Profar’s power. Veterans such as Mike Yastrzemski or Eli White could fill roster spots but would not provide the same offensive impact.
Ultimately, Anthopoulos must balance winning now with protecting the Braves’ future. Whatever decision he makes will shape Atlanta’s outlook for the 2026 season.
Written by
Edited by

Rati Agrawal

